Peginesatide in Patients with Anemia Undergoing Hemodialysis

2013111 citationsJournal Articlehybrid Open Access

Authors

Steven Fishbane · Hofstra University

Brigitte Schiller · Satellite Healthcare (United States)

Francesco Locatelli · Alessandro Manzoni Hospital

Adrian Covic · Spitalul Clinic Dr. C. I. Parhon

Robert Provenzano · St. Clair College

Andrzej Więcek · Medical University of Silesia

Nathan W. Levin

Abstract

Peginesatide, administered monthly, was as effective as epoetin, administered one to three times per week, in maintaining hemoglobin levels in patients undergoing hemodialysis. (Funded by Affymax and Takeda Pharmaceutical; ClinicalTrials.gov numbers, NCT00597753 [EMERALD 1], NCT00597584 [EMERALD 2], NCT00598273 [PEARL 1], and NCT00598442 [PEARL 2].).

Topics & Keywords

Erythropoietin and Anemia Treatment Iron Metabolism and Disorders Hemoglobinopathies and Related Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 368, Issue 4, pp. 307-319

DOI: 10.1056/nejmoa1203165

Field-Weighted Citation Impact: 10.49